引领前沿:多药耐药蛋白(MDR1)与临床药理学——Kim等研究的评论
该评论回顾了转运体在临床药理学中的重要作用,指出肠道、肝脏、肾脏和血脑屏障中的转运体是药物吸收、处置和靶向的守门人。2001年一项开创性研究首次将药物基因组学焦点从药物代谢酶转向药物转运体,证明转运体基因多态性可导致药物药代动力学的个体间差异。
要点
- 转运体是药物吸收、处置和靶向的守门人,分布于肠道、肝脏、肾脏和血脑屏障。
- 2001年开创性研究将药物基因组学焦点从代谢酶转向转运体。
- 转运体基因多态性可导致药物药代动力学的个体间差异。
核心结论
- 转运体在临床药理学中具有重要作用,转运体基因的药物基因组学因素可导致药物药代动力学的个体间差异。
主要发现
- 2001年一项开创性研究首次证明,除药物代谢酶外,转运体基因的药物基因组学因素在药物药代动力学个体间差异中起重要作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the last three decades, transporters have become increasingly recognized for their important roles in clinical pharmacology. As gatekeepers of drug absorption, disposition and targeting, transporters in the intestine, liver, kidney and blood brain barrier have been the subject of many clinical pharmacology studies. A seminal work published in 2001 was among the first studies to shift the focus of pharmacogenomic research from drug metabolizing enzymes to drug transporters, demonstrating that pharmacogenomic factors in genes in addition to drug metabolizing enzymes, and in particular, in transporter genes, could play an important role in interindividual variation in pharmacokinetics of drugs.
引用
- Giacomini KM. Leading the Way: Multi-Drug Resistance Protein (MDR1) and Clinical Pharmacology-Commentary on Kim et al. Clin Pharmacol Ther. 2025. PMID: 40388108. doi:10.1002/cpt.3675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。